Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

H. M. Babiker, I. Brana, D. Mahadevan, T. K. Owonikoko, E. Calvo, D. Rischin, V. Moreno, K. P. Papadopoulos, M. Crittenden, S. Formenti, J. Giralt, P. Garrido Lopez, A. Hervás Morón, K. K. Mohan, M. G. Fury, I. Lowy, E. Stankevich, M. Feng, J. Li, M. Mathias

Producción científica: Articlerevisión exhaustiva

205 Citas (Scopus)
Idioma originalEnglish (US)
Páginas (desde-hasta)viii418
PublicaciónAnnals of oncology : official journal of the European Society for Medical Oncology
Volumen29
DOI
EstadoPublished - oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Citar esto